Top

BMC Neurology

Published in:

01-12-2020 | Parkinson's Disease | Research article

Extrastriatal ¹²³I-FP-CIT SPECT impairment in Parkinson’s disease – the PPMI cohort

Authors: Nicolas Nicastro, Valentina Garibotto, Pierre R. Burkhard

Published in: BMC Neurology | Issue 1/2020

Abstract

Background

Neuropathological data and nuclear medicine imaging show extensive serotonergic impairment in Parkinson’s disease (PD). We undertook a case-controlled analysis of ¹²³I-FP-CIT SPECT images to measure extrastriatal serotonergic transporters (SERT) in PD using the Parkinson’s Progression Markers Initiative (PPMI) cohort.

Methods

We included all PD (n = 154) and Control subjects (n = 62) with available ¹²³I-FP-CIT SPECT imaging and high-resolution T1-weighted MRI for coregistration (PD: mean age 61.6 years, 62% male, disease duration 26 months, MDS-UPDRS III score 22). ¹²³I-FP-CIT SPECT images were processed with PETPVE12 using an exploratory voxel-wise analysis including partial-volume effect correction. Linear regressions were performed in the PD group to assess correlations between region of interest ¹²³I-FP-CIT uptake and clinical motor and non-motor impairment.

Results

Compared to Controls, PD exhibited an uptake reduction in bilateral caudate nucleus, putamen, insula, amygdala and right pallidum (family-wise error (FWE)-corrected p < 0.05). While lower putaminal uptake on the contralateral side to clinically more affected side was associated with higher MDS-UPDRS III score (p = 0.022), we found a trend association between higher geriatric depression scale and lower pallidum uptake (p = 0.09). Higher SCOPA-AUT gastrointestinal subscore was associated with lower uptake in mean putamen and caudate nucleus (p = 0.01 to 0.03), whereas urological subscore was inversely correlated with mean caudate nucleus, putamen, and pallidum uptake (p = 0.002 to 0.03). REM sleep behaviour disorder screening questionnaire was associated with lower ¹²³I-FP-CIT binding in caudate nucleus, putamen and pallidum (all p < 0.05). No significant association was found for Montreal Cognitive Assessment (all p > 0.45) or excessive daytime sleepiness (all p > 0.29).

Conclusions

In addition to the well-established striatal deficit, this study provides evidence of a major extrastriatal ¹²³I-FP-CIT impairment, and therefore of an altered serotonergic transmission in early PD.

Nicastro N, Garibotto V, Burkhard PR. The role of molecular imaging in assessing degenerative parkinsonism - an updated review. Swiss Med Wkly. 2018;148:w14621. https://doi.org/10.4414/smw.2018.14621.PubMedCrossRef

Koch W, Unterrainer M, Xiong G, Bartenstein P, Diemling M, Varrone A, et al. Extrastriatal binding of [(1)(2)(3)I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. Eur J Nucl Med Mol Imaging. 2014;41(10):1938–46. https://doi.org/10.1007/s00259-014-2785-8.PubMedCrossRef

Hornung JP. The human raphe nuclei and the serotonergic system. J Chem Neuroanat. 2003;26(4):331–43.PubMedCrossRef

Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, Mathews WB, et al. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol. 2003;60(9):1223–9. https://doi.org/10.1001/archneur.60.9.1223.PubMedCrossRef

Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain. 2008;131(Pt 1):120–31. https://doi.org/10.1093/brain/awm239.PubMedCrossRef

Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T, et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol. 2007;14(5):523–8. https://doi.org/10.1111/j.1468-1331.2007.01727.x.PubMedCrossRef

Kaasinen V, Joutsa J, Noponen T, Johansson J, Seppanen M. Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson's disease. Neurobiol Aging. 2015;36(4):1757–63. https://doi.org/10.1016/j.neurobiolaging.2015.01.016.PubMedCrossRef

Premi E, Calhoun VD, Garibotto V, Turrone R, Alberici A, Cottini E, et al. Source-based Morphometry multivariate approach to analyze [(123) I]FP-CIT SPECT imaging. Mol Imaging Biol. 2017;19(5):772–8. https://doi.org/10.1007/s11307-017-1052-3.PubMedPubMedCentralCrossRef

Pilotto A, Schiano di Cola F, Premi E, Grasso R, Turrone R, Gipponi S, et al. Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a (123) I-FP-CIT SPECT study. Eur J Nucl Med Mol Imag. 2019;46(8):1642–51. https://doi.org/10.1007/s00259-019-04324-5.CrossRef

10.

Parkinson Progression Marker I. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol. 2011;95(4):629–35. https://doi.org/10.1016/j.pneurobio.2011.09.005.CrossRef

11.

Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Movement Dis. 2008;23(15):2129–70. https://doi.org/10.1002/mds.22340.PubMedCrossRef

12.

Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17(1):37–49.PubMedCrossRef

13.

Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9. https://doi.org/10.1111/j.1532-5415.2005.53221.x.PubMedCrossRef

14.

Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Movement Dis. 2004;19(11):1306–12. https://doi.org/10.1002/mds.20153.PubMedCrossRef

15.

Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–5. https://doi.org/10.1093/sleep/14.6.540.PubMedCrossRef

16.

Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire--a new diagnostic instrument. Movement Dis. 2007;22(16):2386–93. https://doi.org/10.1002/mds.21740.PubMedCrossRef

17.

Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427–42. https://doi.org/10.1212/wnl.17.5.427.PubMedCrossRef

18.

Gonzalez-Escamilla G, Lange C, Teipel S, Buchert R, Grothe MJ. Alzheimer's disease neuroimaging I. PETPVE12: an SPM toolbox for partial volume effects correction in brain PET - application to amyloid imaging with AV45-PET. Neuroimage. 2017;147:669–77. https://doi.org/10.1016/j.neuroimage.2016.12.077.PubMedCrossRef

19.

Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968–80. https://doi.org/10.1016/j.neuroimage.2006.01.021.PubMedCrossRef

20.

Beaudoin-Gobert M, Epinat J, Metereau E, Duperrier S, Neumane S, Ballanger B, et al. Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate. Brain. 2015;138(Pt 9):2632–47. https://doi.org/10.1093/brain/awv183.PubMedCrossRef

21.

Lee JY, Lao-Kaim NP, Pasquini J, Deuschl G, Pavese N, Piccini P. Pallidal dopaminergic denervation and rest tremor in early Parkinson's disease: PPMI cohort analysis. Parkinsonism Relat Disord. 2018;51:101–4. https://doi.org/10.1016/j.parkreldis.2018.02.039.PubMedCrossRef

22.

Buddhala C, Loftin SK, Kuley BM, Cairns NJ, Campbell MC, Perlmutter JS, et al. Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. Ann Clin Transl Neurol. 2015;2(10):949–59. https://doi.org/10.1002/acn3.246.PubMedPubMedCentralCrossRef

23.

Pirker W, Holler I, Gerschlager W, Asenbaum S, Zettinig G, Brücke T. Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT. Movement Dis. 2003;18:1266–72. https://doi.org/10.1002/mds.10531.PubMedCrossRef

24.

Regnault A, Boroojerdi B, Meunier J, Bani M, Morel T, Cano S. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort. J Neurol. 2019;266(8):1927–36. https://doi.org/10.1007/s00415-019-09348-3.PubMedPubMedCentralCrossRef

25.

Maillet A, Krack P, Lhommee E, Metereau E, Klinger H, Favre E, et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease. Brain. 2016;139(Pt 9):2486–502. https://doi.org/10.1093/brain/aww162.PubMedCrossRef

26.

Park SB, Kwon KY, Lee JY, Im K, Sunwoo JS, Lee KB, et al. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions. Neurol Sci. 2019;40(2):311–7. https://doi.org/10.1007/s10072-018-3632-7.PubMedCrossRef

27.

Qamhawi Z, Towey D, Shah B, Pagano G, Seibyl J, Marek K, et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. Brain. 2015;138(Pt 10):2964–73. https://doi.org/10.1093/brain/awv215.PubMedCrossRef

28.

Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. Lancet Neurol. 2017;16(1):66–75. https://doi.org/10.1016/S1474-4422(16)30328-3.PubMedCrossRef

29.

Yousaf T, Pagano G, Niccolini F, Politis M. Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease. J Neurol Sci. 2018;387:220–7. https://doi.org/10.1016/j.jns.2018.02.032.PubMedCrossRef

30.

Pagano G, De Micco R, Yousaf T, Wilson H, Chandra A, Politis M. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. Neurology. 2018;91(10):e894–905. https://doi.org/10.1212/WNL.0000000000006134.PubMedCrossRef

31.

Hinkle JT, Perepezko K, Mills KA, Mari Z, Butala A, Dawson TM, et al. Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease. Parkinsonism Relat Disord. 2018;55:8–14. https://doi.org/10.1016/j.parkreldis.2018.08.010.PubMedPubMedCentralCrossRef

32.

Kim R, Jun JS. Association of autonomic symptoms with presynaptic striatal dopamine depletion in drug-naive Parkinson's disease: an analysis of the PPMI data. Auton Neurosci. 2019;216:59–62. https://doi.org/10.1016/j.autneu.2018.09.005.PubMedCrossRef

33.

Petrovitch H, Abbott RD, Ross GW, Nelson J, Masaki KH, Tanner CM, et al. Bowel movement frequency in late-life and substantia nigra neuron density at death. Movement Dis. 2009;24(3):371–6. https://doi.org/10.1002/mds.22360.PubMedCrossRef

34.

Lavalaye J, Knol RJ, de Bruin K, Reneman L, Janssen AG, Booij J. [123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication. Eur J Nucl Med. 2000;27 3:346–9; doi: https://doi.org/10.1007/s002590050044.

35.

Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck-Smit BL. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nuclear Med. 2007;48(3):359–66.

36.

Rominger A, Cumming P, Brendel M, Xiong G, Zach C, Karch S, et al. Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: a [123 I]beta-CIT SPECT study. Eur Neuropsychopharmacol. 2015;25(6):873–81. https://doi.org/10.1016/j.euroneuro.2014.12.010.PubMedCrossRef

37.

Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y, Zoghbi SS, Baldwin RM, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nuclear Med. 1996;37(7):1129–33.

Title: Extrastriatal 123I-FP-CIT SPECT impairment in Parkinson’s disease – the PPMI cohort
Authors: Nicolas Nicastro
Valentina Garibotto
Pierre R. Burkhard
Publication date: 01-12-2020
Publisher: BioMed Central
Keyword: Parkinson's Disease
Published in: BMC Neurology / Issue 1/2020
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-020-01777-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Extrastriatal ¹²³I-FP-CIT SPECT impairment in Parkinson’s disease – the PPMI cohort

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Rapid formation and rupture of an infectious basilar artery aneurysm from meningitis following suprasellar region meningioma removal: a case report

Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry

Sensor-based systems for early detection of dementia (SENDA): a study protocol for a prospective cohort sequential study

Recurrence and retreatment of anterior communicating artery aneurysms after endovascular treatment: a retrospective study

Cerebrovascular risk factors associated with ischemic stroke in a young non-diabetic and non-hypertensive population: a retrospective case-control study

Head and neck CT angiography to assess the internal carotid artery stealing pathway